Naisana Seyedasli

Dr. Naisana Seyedasli

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2011 in Cell Stem Cell
Verified
Journal Article
Closed access
JCJames J.H. Chong
James J.H. Chong
VCVashe Chandrakanthan
Vashe Chandrakanthan
MXMunira Xaymardan
Munira Xaymardan
Naisana SeyedasliNaisana Seyedasli
Naisana Seyedasli
JLJoan Li
Joan Li
RHRichard P. Harvey
Richard P. Harvey

1 December 2008 in Current Molecular Medicine
Verified
Journal Article
Closed access
PDF file
Naisana SeyedasliNaisana Seyedasli
Naisana Seyedasli
MPMara E. Pitulescu
Mara E. Pitulescu
MKMichael Kessel
Michael Kessel
Large numbers and quantities of different, small RNA molecules are present in the cytoplasm of animal and plant cells. One subclass of these molecules is represented by the noncoding microRNAs. Since their discovery in the 1990s a multitude of basic information has accumulated, which has identified their function in post-transcriptional control, either via degradation or translational inhibition of target mRNAs. This function is in most of the cases a finetuning of gene expression, working in parallel with transcriptional regulatory processes. MicroRNA expression profiles are highly dynamic during embryonic development and in adulthood. Misexpression of microRNAs can perturb embryogenesis, organogenesis, tissue homeostasis and the cell cycle. Evidence from gain- and loss-of function studies indicates roles for microRNAs in pathophysiologic states including cardiac hypertrophy, muscle dystrophy, hepatitis infection, diabetes, Parkinson syndrome, hematological malignancies and other types of cancer. In this review, we focus on studies addressing the role of various microRNAs in heart, muscle, liver, pancreas, central nervous system, and hematopoiesis.

1 January 2020 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
STSujitha Thavapalachandran
Sujitha Thavapalachandran
SGStuart M Grieve
Stuart M Grieve
RHRobert D. Hume
Robert D. Hume
TLThi Yen Loan Le
Thi Yen Loan Le
KRKalyan Raguram
Kalyan Raguram
JCJames J. H. Chong
James J. H. Chong
Recombinant human platelet-derived growth factor-AB improves cardiac function and survival after myocardial infarction in a porcine model.


27 June 2025 in The AAPS Journal
Verified
Journal Article
Open access
PDF file
HGHany Sadek Ayoub Ghaly
Hany Sadek Ayoub Ghaly
Naisana SeyedasliNaisana Seyedasli
Naisana Seyedasli
PVPegah Varamini
Pegah Varamini
Herein, we report a new modified nanoprecipitation method for the fabrication of water-dispersible Poly(lactic-co-glycolic acid) (PLGA) nanoparticles encapsulating three poorly water-soluble anticancer agents as model drugs: paclitaxel (PTX), docetaxel (DTX) or curcumin (Cur). These nanoparticles were water dispersible with favourable size for anticancer applications (below 200 nm) and relatively high drug loading (6.3–8.9%). These nanoparticles were stable for four weeks in solid state and up to 48 h when dispersed in water. PTX and Cur nanoparticles showed a very minimal release of the payload during a 72-h in vitro release study. The new method also yielded reproducible results across three different batches of each type of nanoparticles and following three times upscaling of PTX nanoparticles. PTX and Cur nanoparticles were more effective than the free drugs against MDA-MB-231 cells (p < 0.05). In addition, PTX nanoparticles showed a significant enhanced induction of early apoptosis in MDA-MB-231 cells (42.3%) in comparison to free PTX (23.7%, p < 0.05). Both flow cytometry and confocal microscopy confirmed the uptake of the nanoparticles by MDA-MB-231 cells. In conclusion, our modified nanoprecipitation method produces PLGA nanoparticles loaded with different anticancer agents and suitable for cancer therapy. Graphical Abstract

1 July 2007 in Molecular and Cellular Biology
Verified
Journal Article
Closed access
PDF file
LLLingfei Luo
Lingfei Luo
YUYvonne Uerlings
Yvonne Uerlings
NHNicole Happel
Nicole Happel
Naisana SeyedasliNaisana Seyedasli
Naisana Seyedasli
HKHendrik Knoetgen
Hendrik Knoetgen
MKMichael Kessel
Michael Kessel
The geminin protein functions both as a DNA rereplication inhibitor through association with Cdt1 and as a repressor of Hox gene transcription through the polycomb pathway. Here, we report that the functions of avian geminin are coordinated with and regulated by cell cycle-dependent nuclear-cytoplasmic shuttling. In S phase, geminin enters nuclei and inhibits both loading of the minichromosome maintenance (MCM) complex onto chromatin and Hox gene transcription. At the end of mitosis, geminin is exported from nuclei by the exportin protein Crm1 and is unavailable in the nucleus during the next G1 phase, thus ensuring proper chromatin loading of the MCM complex and Hox gene transcription. This mechanism for regulating the functions of geminin adds to distinct mechanisms, such as protein degradation and ubiquitination, applied in other vertebrates.